Browse the evidence

Chronic administration of GIP receptor agonists (specifically GIP108) causes functional desensitization of the GIP receptor in pancreatic islets, reducing the efficacy of subsequent glucose-lowering challenges.

Long-term use of GIP-based therapies (like tirzepatide) triggers a biological adaptation where the pancreas becomes less responsive to the drug's glucose-lowering signal. This is a known mechanism called desensitization. However, the drug still promotes weight loss, suggesting the benefit comes from multiple pathways, not just pancreatic sensitivity. If glycemic control wanes, dose adjustments may be necessary.

GLP-1 receptor agonists increase perioperative aspiration risk due to delayed gastric emptying, requiring specific holding protocols before elective surgery.

If you are having elective surgery while taking GLP-1 medications, tell your surgeon and anesthesiologist. You may need to hold your medication before surgery to reduce the risk of aspiration. Follow the specific holding instructions provided by your medical team.

SGLT2 inhibitors reduce blood pressure and cardiovascular risk, potentially through central sympatho-inhibition, but do not necessarily reduce muscle sympathetic nerve activity (MSNA) in humans.

SGLT2 inhibitors (like Jardiance or Farxiga) lower blood sugar and protect the heart. While they work by removing glucose through urine, they may also have subtle effects on brain pathways that help lower blood pressure.

Tirzepatide (a dual GIP/GLP-1 receptor agonist) significantly improves hepatic steatosis and increases the likelihood of MASH resolution without worsening fibrosis in patients with non-cirrhotic MASH.

If you have MASH without cirrhosis, ask your doctor about tirzepatide. Clinical trials show that weekly injections of 5-15mg can significantly resolve MASH and improve liver fat without worsening fibrosis. This is a promising option for managing liver health in addition to blood sugar and weight.

Resmetirom is approved for adults with non-cirrhotic MASH and advanced liver fibrosis (stage ≥ 2) and has shown histological efficacy in addressing steatohepatitis and fibrosis.

If you have MASH with advanced fibrosis but no cirrhosis, ask your doctor about resmetirom. It is an approved treatment that has been shown to improve both steatohepatitis and fibrosis with a favorable safety profile.

GLP-1 RAs improve histological markers of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and reduce liver fat in patients with MASLD, MetALD, and ALD.

If you have fatty liver disease (MASLD/MASH), GLP-1 medications like Semaglutide or Liraglutide can significantly improve liver inflammation and fat content, often leading to MASH resolution. This is especially beneficial if you also have obesity or Type 2 Diabetes. Discuss these options with your hepatologist, noting that while they improve liver histology, they may not always reverse advanced fibrosis.

Peripheral GLP-1 receptor agonists (GLP-1RAs) exert brain-mediated anorectic effects primarily via access to circumventricular organs (CVOs) like the area postrema and median eminence, rather than crossing the blood-brain barrier (BBB) or blood-cerebrospinal fluid barrier (BCB).

GLP-1 medications like Semaglutide and Liraglutide reduce appetite by signaling from the gut to specific brain regions (CVOs) via the vagus nerve, rather than crossing into the brain tissue itself. This explains why they are effective for weight loss even though very little drug actually enters the cerebrospinal fluid.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) cause dose-dependent gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) primarily during dose escalation, leading to discontinuation in 3-17% of non-diabetic users.

If you are using a GLP-1 medication like semaglutide or tirzepatide, expect gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These symptoms are common but usually mild and transient. To manage them, follow a slow titration schedule, eat smaller, low-fat meals, and stay hydrated. Most people adapt over time, but if side effects are severe, consult your doctor about adjusting the dose.

Intermittent Hypoxia (IH) is a key pathogenic factor in OSA that drives cardiovascular and metabolic disease through vascular remodelling, atherosclerosis, and insulin resistance, independent of obesity.

The repeated drops in oxygen during sleep (Intermittent Hypoxia) are what actually damage your heart and metabolism, not just the breathing stops themselves. Managing OSA is crucial to prevent this cycle of damage.

Cholecystokinin (CCK) acts as a primary intestinal satiety signal that regulates food intake via CCK1 receptors on afferent vagal fibers, with its secretion dynamics altered by bariatric surgery but remaining largely unchanged in obesity.

CCK is your body's natural 'fullness' signal from the gut. In obesity, this signal isn't broken; levels are normal. However, bariatric surgery can enhance this signal significantly. Focus on dietary strategies that naturally stimulate CCK release (like protein/fat intake) rather than assuming a hormonal defect.

GLP-1 receptor agonists, SGLT2 inhibitors, and pioglitazone are recommended pharmacotherapies for MASLD/MASH management.

If lifestyle changes are not enough, ask your doctor about GLP-1 RAs, SGLT2 inhibitors, or pioglitazone. These medications can help manage metabolic health and reduce liver disease progression.

Physiological levels of reactive oxygen species (ROS), specifically hydrogen peroxide (H2O2), act as essential signaling molecules that augment insulin sensitivity and glucose uptake in skeletal muscle by inhibiting negative regulators like PTP1B and activating Akt.

Do not assume that high-dose antioxidant supplements improve insulin sensitivity. In healthy or early-stage metabolic contexts, your body relies on low levels of oxidative stress (ROS) to signal insulin to move glucose into muscles. Blocking this signal with excessive antioxidants may actually impair glucose uptake and metabolic adaptation.

Mechanistically, GLP-1RA-induced muscle loss is driven by reduced protein intake, negative energy balance, and suppressed mTOR signaling due to lower insulin/IGF-1 levels, rather than direct myotoxicity.

The muscle loss isn't because the drug attacks muscle directly; it's because you eat less, have less energy, and your body's growth signals (like insulin) are lower. This is why eating enough protein and lifting weights is crucial to counteract these natural signals.

Small-molecule GLP-1 receptor agonists (e.g., orforglipron) are pharmacologically inactive in standard wild-type mice due to species-specific receptor binding differences, requiring humanized GLP-1 receptor (hGLP1R) mouse models to accurately predict human metabolic efficacy.

If you are evaluating or using small-molecule GLP-1 drugs (like orforglipron), standard animal testing will not show their effects. These drugs require a humanized receptor to work in mice. This highlights why human clinical trials are essential for this specific class of drugs, as animal models cannot predict their efficacy.

In humanized GLP-1 receptor mice, small-molecule GLP-1 receptor agonists (e.g., orforglipron) produce metabolic effects (weight loss, glucose tolerance) comparable to peptide-based agonists (e.g., semaglutide).

Small-molecule GLP-1 drugs can work as well as peptide drugs in terms of metabolic effects, provided they bind to the correct receptor. This humanized mouse model confirms that oral small-molecule options have the potential to match the efficacy of injectable peptides.

Discontinuation of GLP-1 medications leads to rapid weight regain (up to two-thirds of prior loss) and worsening cardiometabolic health, disproportionately affecting underserved communities.

Stopping GLP-1 medication often leads to regaining up to two-thirds of the weight lost and worsening health. It is crucial to have a sustainable plan for medication access or transition to maintain long-term health.

Semaglutide promotes sex-dependent adipose tissue remodeling, with females showing more pronounced reductions in visceral fat mass and greater potency in locomotor activity increases compared to males.

Men and women may respond differently to semaglutide. This study suggests women might experience greater reductions in visceral fat and larger increases in physical activity compared to men at similar doses. This highlights the importance of sex-specific considerations in obesity treatment.

Incretin-based anti-obesity medications (GLP-1 and GIP/GLP-1 receptor agonists) cause gastrointestinal adverse effects (nausea, diarrhea, constipation) in 65–84% of patients, primarily through delayed gastric emptying and central appetite signaling activation.

If you start a GLP-1 or GIP medication, expect stomach issues like nausea or diarrhea in the first few weeks. This is very common (affecting up to 84% of users). To manage it, start with a low dose and increase slowly. Eat small, low-fat meals, stay hydrated, and avoid spicy or fatty foods. Most symptoms improve as your body adjusts.

Rapid weight loss, whether from very-low-calorie diets or bariatric surgery, significantly increases the risk of gallstone formation (cholelithiasis) due to bile supersaturation and reduced gallbladder motility.

If you lose weight very quickly (e.g., through surgery or extreme dieting), you are at higher risk for gallstones. To prevent this, aim for gradual weight loss. If you have had bariatric surgery, doctors often prescribe Ursodeoxycholic acid (UDCA) for 6 months to prevent gallstones.

Administering GLP-1 receptor agonists (liraglutide or semaglutide) during the proestrus/estrus (P/E) phase of the estrous cycle significantly enhances food intake suppression and body weight loss compared to administration during the metestrus/diestrus (M/D) phase in female rats.

If you are using a GLP-1 medication like semaglutide or liraglutide, your body's natural hormonal cycle may affect how well it works. This research suggests that taking your dose during the weeks when estrogen is highest (typically the first half of the cycle) might lead to greater appetite suppression and weight loss than taking it during other weeks. While more research in humans is needed, you might consider discussing cycle-timing with your provider to see if optimizing the timing of your injections could enhance your results.

Inhibiting PCSK9, NF-κB, and NLRP3 reduces cholesterol and inflammation, providing cardioprotection.

For cardiovascular protection, medications that lower cholesterol (like PCSK9 inhibitors) and reduce inflammation (targeting NF-κB or NLRP3) are effective strategies. These treatments help manage risk factors associated with heart disease and metabolic disorders. Discuss with your healthcare provider if these targeted therapies are suitable for your cardiovascular health.

Dulaglutide, subcutaneous semaglutide, and tirzepatide exhibit comparable risks of severe gastrointestinal adverse events (including acute pancreatitis, biliary disease, bowel obstruction, gastroparesis, and severe constipation) in adults with type 2 diabetes.

If you are choosing between dulaglutide, semaglutide, or tirzepatide for type 2 diabetes, do not expect a significant difference in the risk of serious stomach problems (like pancreatitis or bowel obstruction) between them. They all carry a similar, low risk of severe GI events, though mild nausea or diarrhea is common with all. Your choice should likely be based on efficacy (weight loss/glycemic control), cost, and tolerability of mild side effects rather than fear of severe GI complications.

Obesity promotes cancer development by increasing DNA damage and impairing DNA repair mechanisms, while simultaneously activating pro-survival signaling pathways that prevent the elimination of damaged cells.

Maintaining a healthy weight is a critical strategy for reducing cancer risk, not just for metabolic health. Obesity creates a biological environment that damages DNA and prevents the body from fixing those damages, while also protecting damaged cells from dying. Weight management interventions should be viewed as a direct cancer prevention strategy.

Periconceptional exposure to GLP-1 receptor agonists (liraglutide or semaglutide) is associated with an increased risk of preterm birth, but this risk is confined to women using the medication for diabetes treatment and is not observed in women using it for weight management.

If you are using a GLP-1 medication (like Ozempic or Saxenda) and planning pregnancy, talk to your doctor. If you have diabetes, the increased risk of early delivery is likely due to the diabetes, not the drug, so managing your blood sugar is key. If you are using it for weight loss, current large-scale data shows no increased risk of early delivery, which may help alleviate anxiety about inadvertent exposure.